



ASX ANNOUNCEMENT

5 JULY 2022

APPOINTMENT OF CASSANDRA HARRISON TO VICE PRESIDENT CLINICAL OPERATIONS AND DATA MANAGEMENT

Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has appointed Ms Cassandra Harrison to the position of Vice President (VP) Clinical Operations and Data Management.

Ms Harrison joins Chimeric with more than 10 years experience in clinical operations, compliance, and data management. Until recently, Ms Harrison was Vice President of Clinical Operations and Data Management at ImmunoGenesis, Inc., an immuno-oncology company, where she built both the clinical operations and data management departments and provided oversight on all aspects of data management and clinical operations.

Ms Harrison has extensive cell therapy experience from her previous role at Bellicum Pharmaceuticals where she was part of the pioneering team exploring CAR T cell therapies in solid tumours. At Bellicum she led, managed and implemented organisational resources, oversaw data management and outsourcing across multiple clinical programs.

Ms Harrison holds active nursing licensures in North Carolina, Massachusetts, and Pennsylvania. She also has a Master of Business Administration from Apsen University, Colorado, and a Master of Public Health from Walden University, Minnesota.

This VP Clinical Operations role will focus on leading Chimeric’s successful execution of all clinical program operations as it moves forward with a portfolio of four phase 1 clinical trials. Chimeric recently established a A\$30 million equity funding agreement with leading global investor, L1 Capital Global Opportunities Master Fund which will be used to progress the clinical pipeline.

Chimeric’s CEO & Managing Director Jennifer Chow said “We are excited to welcome Cassandra as the Vice President Clinical Operations at Chimeric, a newly created but critically important position within our organisation. She is a high calibre addition to our management team who will play a key role in advancing our clinical pipeline at this exciting and pivotal time for the business.”



ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent / progressive glioblastoma. Initial positive data has been presented on patients treated in the first two dose levels of the trial. A 2nd CLTX CAR T phase 1 clinical trial is planned to begin in metastatic melanoma with future expansion to additional solid tumours.

CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in neuroendocrine tumours, colorectal, gastroesophageal and gastric cancer.

CHM 0201 (CORE-NK platform) is a clinically validated, off the shelf natural killer (NK) cell platform. Data from the complete phase 1 clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. From the CORE-NK platform, Chimeric will initiate development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials in solid tumours and blood cancers.

Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.



CONTACT

Investors

Jennifer Chow
Chief Executive Officer and Managing Director
Chimeric Therapeutics
T: + 1 9087238387
E: jchow@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Paul Hopper
Executive Chairman
Chimeric Therapeutics
T: + 61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au